Getting a Referral for NHS Weight Loss Injections: How It Works

You've asked your GP, and the answer was complicated

This is the situation a huge number of people find themselves in right now. You've read about Mounjaro or Wegovy, you've raised it with your GP, and the response wasn't a straight yes. That's not unusual, and it's worth understanding why before deciding what to do next.

The NHS rollout of weight loss injections is following a phased schedule tied to NICE guidance. For tirzepatide, NICE's appraisal TA1026 currently recommends NHS access for adults with a BMI of 40 or above alongside four or more of a defined set of conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. From around June 2026, that opened to adults with a BMI between 35 and 39.9 meeting the same four-condition threshold. Further cohorts follow in 2027. For semaglutide (Wegovy), the NICE recommendation under TA875 sits within specialist weight management services only, with its own criteria and a two-year treatment cap.

What this means in practice is that even if you're living with obesity and a weight-related health condition, you may not fall into an open cohort yet. And even if you do, your GP practice has to opt in (participation is currently optional) and it must have wraparound diet and activity support in place. These are real barriers that explain why so many people are still waiting despite meeting some, but not all, of the requirements. The referral process itself is worth reading through carefully if you're still pursuing the NHS route.

What the phased NHS rollout actually means for your referral

A question our prescribers hear most weeks is: "My BMI is over 35 and I have diabetes, why won't my GP refer me?" The honest answer is that meeting one version of the criteria isn't always enough; the full picture has to align.

For tirzepatide on the NHS, the criteria aren't just about BMI, they require a specific number of qualifying comorbidities from that fixed list, and from 1 April 2026 GP practices can prescribe under the updated QOF contract, but only those that have signed up and built the required support pathway. Scotland, Wales and Northern Ireland operate under different thresholds and commissioning arrangements, so if you're outside England, the specific criteria in your area will differ. The newer NHS access routes are still bedding in across many areas, and waiting lists for specialist services for semaglutide are commonly long. Whether you currently qualify depends on your exact BMI, your comorbidities, your GP practice's participation status, and which cohort phase is active. Ethnic background thresholds are 2.5 kg/m² lower throughout, under both the NICE and NHS England guidance, so South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds may qualify at a lower BMI. The NICE tirzepatide appraisal (TA1026) is the clearest public statement of these thresholds, and it's worth reading the recommendations chapter directly if you want to check your position precisely.

None of this is a criticism of the NHS. The phased approach reflects the scale of demand and the need to build clinical infrastructure. But it does mean that many people in genuine medical need are currently outside the scope of what their GP can offer.

The private prescription route: what it is and how the clinical assessment works

If you don't meet the current NHS criteria, or you'd rather not join what could be a long waiting list, a private prescription from a registered pharmacy is a lawful alternative, as long as it's done properly. These are prescription-only medicines, so the process still has to include a genuine clinical assessment. No reputable prescriber skips that step.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber. That person reads your health information, checks for contraindications, and makes a clinical decision. It's not automated. If approved, your treatment is dispatched the same day (for orders placed before midday, Monday to Friday) and arrives via tracked DPD the next working day, in plain packaging. You can verify our pharmacy on the GPhC register at registration number 9012878.

The private eligibility criteria broadly follow the licensed indications: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. A prescriber assesses the whole picture, not just the BMI number. If you're curious about the realistic cost of private treatment, this page covers what private weight loss injections typically cost in the UK and what that price should include. For a broader look at the treatment options available, our weight loss injections overview explains how both Mounjaro and Wegovy work and what the clinical evidence shows. If you need treatment quickly, next-day delivery is available for orders placed before 12pm.

Whatever route you're weighing up, the NHS England guidance on weight management injections is a solid reference for understanding what the NHS pathway expects and why it's structured as it is.